Early discharge after primary percutaneous coronary intervention: The added value of N-terminal pro-brain natriuretic peptide to the zwolle risk score

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Schellings, Dirk A A M ^a   Adiyaman, Ahmet ^a   Giannitsis, Evangelos ^b   Hamm, Christian ^c   Suryapranata, Harry ^a,d   Ten Berg, Jurrien M ^e   Hoorntje, Jan C A ^a   Van't Hof, Arnoud W J ^a  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Discharge; Mortality; NT proBNP; PCI; Risk stratification; ST elevation myocardial infarction; Zwolle risk score

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TIROFIBAN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TYROSINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVERSION; CONTROLLED STUDY; DEFIBRILLATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOSPITAL DISCHARGE; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ZWOLLE RISK SCORE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; HEMORRHAGE; LENGTH OF STAY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; AREA UNDER CURVE; BIOMARKERS; DECISION SUPPORT TECHNIQUES; FEMALE; HEMORRHAGE; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 84939462776     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001089     Document Type: Article

References (25)

1. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, Balestrini C, Stone G, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Sachs D, Mason D, Grines LL, O'Neill W. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;5: 967-972.
2. Branca G, Capodanno D, Capranzano P, Barbagallo R, Seminara D, Licciardello G, Tamburino C. Early discharge in acute myocardial infarction after clinical and angiographic risk assessment. J Cardiovasc Med (Hagerstown). 2008;9:858-861.
3. Jirmar R, Widimsky P, Capek J, Hlinomaz O, Groch L. Next day discharge after successful primary angioplasty for acute ST elevation myocardial infarction. An open randomized study "Prague-5." Int Heart J. 2008;49:653-659.
4. Kotowycz MA, Cosman TL, Tartaglia C, Afzal R, Syal RP, Natarajan MK. Safety and feasibility of early hospital discharge in ST-segment elevation myocardial infarction: a prospective and randomized trial in low risk primary percutaneous coronary intervention patients (The Safe-Depart Trial). Am Heart J. 2010;159:117.e1-117.e6.
5. Laarman GJ, Dirksen MT. Early discharge after primary percutaneous coronary intervention. Heart. 2010;96:584-587.
6. Jones DA, Rathod KS, Howard JP, Gallagher S, Antoniou S, De Palma R, Guttmann O, Cliffe S, Colley J, Butler J, Ferguson E, Mohiddin S, Kapur A, Knight CJ, Jain AK, Rothman MT, Mathur A, Timmis AD, Smith EJ, Wragg A. Safety and feasibility of hospital discharge 2 days following primary percutaneous intervention for ST-segment elevation myocardial infarction. Heart. 2012;98:1722-1727.
7. De Luca G, Suryapranata H, van't Hof AWJ, de Boer MJ, Hoorntje JCA, Dambrink JHE, Gosselink ATM, Ottervanger JP, Zijlstra F. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation. 2004;109:2737-2743.
8. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206-3212.
9. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-1969.
10. Tapanainen JM, Lindgren KS, Makikallio TH, Vuolteenaho O, Leppaluoto J, Huikuri HV. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol. 2004;43:757-763.
11. Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald E. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335-339.
12. Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart. 2008;94:40-43.
13. Ang D, Wei L, Kao M, Lang C, Struthers A. A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification. Heart. 2009;95:1836-1842.
14. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliot J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786-2792.
15. van't Hof AWJ, ten Berg JM, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JHE, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with STelevation myocardial infarction undergoing primary angioplasty (On-Time 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537-546.
16. van't Hof AWJ, Hamm C, Rasoul S, Guptha S, Paolini JF, ten Berg JM, on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroInterv. 2007;3: 371-380.
17. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons; 1987.
18. The Task Force on the management of ST-segment elevation myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. Available at: www.escardio.org/guidelines. Eur Heart J. 2012;33:2569-2619.
19. Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek Z, Horszczaruk GJ, Kochman J, Rudowski R, Opolski G. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary PCI. Am Heart J. 2004;148:655-662.
20. Hong SN, Ahn Y, Hwang SH, Yoon NS, Lee SR, Moon JY, Kim KH, Hong YJ, Park HW, Kim JH, Jeong MH, Cho JG, Park JC, Kang JC. Usefulness of preprocedural N-terminal pre-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol. 2007;100: 631-634.
21. Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, Aylward P, Granger CB, Van de Werf F, Armstrong PW. International differences in evolution of early discharge. Lancet. 2004;363:511-517.
22. Barchielli A, Marchionni N, Carraba N, Margheri M, Santoro GM, Olivotto I, Buiatti E; AMI-Florence Working Group. Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMIFlorence Registry, Italy. Int J Cardiol. 2007;114:57-63.
23. Heggunje PS, Harjai KJ, Stone GW, Mehta RH, Marsalese DL, Boura JA, O'Neill WW, Grines CL. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1400-1407.
24. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557-567.
25. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-1159.